Multiple sclerosis Archives

News and Trends 24 Aug 2015

Novartis signs $1Bn deal for GSK’s Multiple Sclerosis Antibody

Is this Novartis‘ next blockbuster? The Swiss company has acquired GlaxoSmithKline‘s (GSK) immunosuppressive antibody Ofatumumab for up to $1Bn. The new drug allows Novartis to enter the multiple sclerosis market for the third time. Earlier this year, Novartis purchased GSK’s oncology portfolio for $16 billion (€14Bn), including the fully human monoclonal anitbody Ofatumumab, which is […]

August 24, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Jun 2015

After two failed IPOs, Mapi Pharma raised €9 Million from private investors

Private investors have finally backed Mapi Pharma’s project with €9.1M. Shavit Capital has led the Series A financing round to support the company’s clinical development plans. The cash raised is sufficient to advance the company’s lead product Glatiramer Acetate (GA) Depot to its Phase III. The Israeli company has a bitter record of failed NASDAQ […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 May 2015

Genzyme joins the never-ending list of Ablynx’ partners

Genzyme is joining Ablynx’ partner list, which already includes AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Sanofi subsidiary now wants to try out the Nanobody technology of Ablynx against a target at the origin of multiple sclerosis. Genzyme wants to investigate nanobodies against a target that specifically aligns with Genzyme’s early-stage multiple […]

May 22, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 4 Mar 2015

Alkermes presents its new treatment of Alzheimer’s agitation

Alkermes reveals a new drug candidate, ALKS 7119, for treatment of Alzheimer’s agitation, depression and other central nervous system (CNS) diseases. Alkermes has successfully completed preclinical development and expects to initiate the first clinical study of its newest candidate, ALKS 7119, in the third quarter of 2015. ALKS 7119 has a multivalent mechanism of action […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Feb 2015

Ipsen buys an option to Acquire Canbex

Canbex, a spin-off of University College London (UCL) that raised a Series A financing of €2.8M in 2013 from MS Ventures, may become part of Ipsen. The French giant payed €6M upfront for the option to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment […]

February 25, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Dec 2014

Will there be a New Merck-Serono?

GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought an option for €38M on the marketing rights outside the United States and Japan for a treatment against multiple sclerosis. Could GeNeuro become the next Merck-Serono? This amount will allow the Swiss company to continue the clinical development of this molecule. […]

December 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 20 Aug 2014

Danish biotech Forward Pharma files for $200m IPO

Forward Pharma, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The number of shares to […]

August 20, 2014 - 1 minutemin - By Joachim Eeckhout

News and Trends 15 Aug 2014

Active Biotech and Teva together in a Phase II clinical trial against Huntington’s disease

Active Biotech announced today that its partner Teva Pharmaceutical will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease. Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed primarily for the treatment of relapsing-remitting multiple sclerosis […]

August 15, 2014 - 1 minutemin - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Multiple sclerosis

Novartis signs $1Bn deal for GSK’s Multiple Sclerosis Antibody

After two failed IPOs, Mapi Pharma raised €9 Million from private investors

Genzyme joins the never-ending list of Ablynx’ partners

Alkermes presents its new treatment of Alzheimer’s agitation

Ipsen buys an option to Acquire Canbex

Will there be a New Merck-Serono?

Danish biotech Forward Pharma files for $200m IPO

Active Biotech and Teva together in a Phase II clinical trial against Huntington’s disease

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!